Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prodromal Clear all
Enrolling by invitation Not applicable Interventional

The Digital Memory Notebook

NCT04240665
View directory record Official record
Conditions
Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Subjective Cognitive Complaints
Interventions
Digital Memory Notebook (DMN) Application
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2Phase 3 Interventional

Aripiprazole Treatment of Prodromal Patients

NCT00237874
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
Aripiprazole
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 31, 2026, 6:50 AM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional

DMHI for At-Risk College Students

NCT06608498
View directory record Official record
Conditions
Prodromal Symptoms, Psychosis
Interventions
SPARK Coping
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

NCT02760602
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
98
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 31, 2026, 6:50 AM EDT
Enrolling by invitation No phase listed Observational

Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis

NCT03970005
View directory record Official record
Conditions
Prodromal Schizophrenia
Interventions
Step-Based Care Model
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
12 Years to 25 Years
Enrollment
100 participants
Timeline
2019 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Early Detection and Intervention for the Prevention of Psychosis

NCT00531518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions
aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
Drug · Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 25 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 31, 2026, 6:50 AM EDT
Active, not recruiting No phase listed Observational

The Syn-Sleep Study

NCT05757206
View directory record Official record
Conditions
REM Sleep Behavior Disorder (iRBD)
Interventions
Syn-One Test
Diagnostic Test
Lead sponsor
CND Life Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT01773239
View directory record Official record
Conditions
Schizophrenia
Interventions
TARA computer-based exercises
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 31, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

NCT06993142
View directory record Official record
Conditions
Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases, Parkinsonian Disorders, Genetic Predisposition
Interventions
Increase of physical activity volume and intensity with the use of a motivational smartphone application
Behavioral
Lead sponsor
Radboud University Medical Center
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Enrolling by invitation Phase 2 Interventional

Alzheimer's Tau Platform: Regimen A - AADvac1

NCT07167966
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
Interventions
AADvac1, Donanemab
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Active, not recruiting Phase 2 Interventional

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

NCT04148391
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
Interventions
Placebo Oral Capsule, NYX-458
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
50 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
48
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 31, 2026, 6:50 AM EDT
Active, not recruiting Not applicable Interventional

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

NCT04338152
View directory record Official record
Conditions
Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
Interventions
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional

MBCT and CBT for Youth at High Risk for Mood and Psychotic Disorders: a Randomized Controlled Trial

NCT05070052
View directory record Official record
Conditions
Mood Disorders, Prodromal Symptoms, Bipolar Disorder, Parents, Clinical High Risk
Interventions
cognitive behavioral therapy, mindfulness-based cognitive therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 25 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT02670083
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
66
States / cities
Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NCT00169988
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychotic Disorders
Interventions
risperidone, sertraline-primary
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 31, 2026, 6:50 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

NCT04477785
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

NCT04867616
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Cognitive Markers in Prodromal MS

NCT05543915
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Active tDCS
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
23 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Self-Care for Dementia Caregivers

NCT05309577
View directory record Official record
Conditions
Aging, Mental Disorder, Eating, Healthy, Physical Inactivity, Prodromal Symptoms, Sleep, Alzheimer Disease, Dementia, Circadian Rhythm Disorders
Interventions
Behavioral Self-Monitoring + Motivational Interviewing
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 31, 2026, 6:50 AM EDT